Top

Published in:

01-10-2016 | Case report

Diffuse large B-cell lymphoma, not otherwise specified presenting with bone and bone marrow involvement in the absence of lymphadenopathy

Authors: Hisaharu Shikata, Masaki Maruta, Masahiko Kaneko

Published in: International Cancer Conference Journal | Issue 4/2016

Abstract

A 74-year-old woman visited our hospital because of right chest pain and fatigue. Laboratory examinations revealed pancytopenia and an elevated level of serum lactate dehydrogenase. Although bone lesions were detected by computed tomography, there was no lymphadenopathy. Blastoid cells were evident in the bone marrow. From the patient’s medical history and results of immunohistological and chromosomal analysis, she was diagnosed as having diffuse large B-cell lymphoma, not otherwise specified. This form of presentation of diffuse large B-cell lymphoma is very rare, and emphasizes the need for careful evaluation of such cases, including bone marrow biopsy for accurate diagnosis.

Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032CrossRefPubMedPubMedCentral

Harada S, Suzuki R, Uehira K et al (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447CrossRefPubMed

Matolcsy A, Chadburn A, Knowles DM (1995) De novo CD5-positive and Richter’s syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207–216PubMedPubMedCentral

Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

Yamaguchi M, Seto M, Okamoto M et al (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed

Niitsu N, Okamoto M, Tamaru JI et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed

Miyazaki K, Yamaguchi M, Suzuki R et al (2011) CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22:1601–1607CrossRefPubMed

Campbell J, Seymour JF, Matthews J et al (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76:473–480CrossRefPubMed

Moller MB, Pedersen NT, Christensen BE (2004) Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation––a population-based study of 1575 cases. Br J Haematol 124:151–159CrossRefPubMed

10.

Conlan MG, Bast M, Armitage JO et al (1990) Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 8:1163–1172PubMed

11.

Nakamura N, Kuze T, Hashimoto Y et al (2001) CD5-positive diffuse large B-cell lymphoma presenting in bone marrow without lymphadenopathy. J Clin Exp Hematopathol 41:73–80CrossRef

12.

Mutreja D, Pati HP, Bansal D et al (2014) Aberrant immunophenotypic expression of CD5 in a case of B acute lymphoblastic leukemia: a case report. Indian J Hematol Blood Transfus 30:212–214CrossRefPubMedPubMedCentral

13.

Ohno H, Fukuhara S (1997) Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leuk Lymphoma 27:53–63CrossRefPubMed

14.

Deucher AM, Qi Z, Yu J et al (2015) BCL6 expression correlates with the t(1;19) translocation in B-lymphoblastic leukemia. Am J Clin Pathol 143:547–557CrossRefPubMed

15.

Kramer MH, Hermans J, Wijburg E et al (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152–3162PubMed

16.

Kajiura D, Yamashita Y, Mori N (2007) Diffuse large B-cell lymphoma initially manifesting in the bone marrow. Am J Clin Pathol 127:762–769CrossRefPubMed

17.

Shimada K, Kinoshita T, Naoe T et al (2009) Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895–902CrossRefPubMed

18.

Murase T, Yamaguchi M, Suzuki R et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485CrossRefPubMed

19.

Takahashi H, Tomita N, Yokoyama M et al (2012) Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 118:4166–4172CrossRefPubMed

20.

Sehn LH, Scott DW, Chhanabhai M et al (2011) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29:1452–1457CrossRefPubMed

Title: Diffuse large B-cell lymphoma, not otherwise specified presenting with bone and bone marrow involvement in the absence of lymphadenopathy
Authors: Hisaharu Shikata
Masaki Maruta
Masahiko Kaneko
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: International Cancer Conference Journal / Issue 4/2016
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-016-0254-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

A case report of primary malignant melanoma of male urethra with distinct appearance in multiple regions

Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs

Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy

Late recurrence of gastric cancer in the ovary and uterine cervix

Keynote webinar | Spotlight on antibody–drug conjugates in cancer